THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.13] ID: TIP-MED-000245

Tranexamic Acid (Antifibrinolytic Haemorrhage Control)

Active Ingredient / Scientific Identity: Tranexamic Acid • Class: Antifibrinolytic Synthetic Lysine Analogue (Plasminogen Activation Inhibitor)

⚖️ Compare Profile
Generic / Entity NameTranexamic Acid (Antifibrinolytic Haemorrhage Control) ([12.13])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassAntifibrinolytic Synthetic Lysine Analogue (Plasminogen Activation Inhibitor)
Available Dosage FormsTablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Tranexamic Acid (Antifibrinolytic Haemorrhage Control) (TIP-MED-000245, Reference Code [12.13]) is classified under Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Antifibrinolytic Synthetic Lysine Analogue (Plasminogen Activation Inhibitor). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.13], p. 161): Trapic, Pause, Texakind, Trenaxa — Strengths & Dosage Forms: Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.13], p. 161): Trapic, Pause, Texakind, Trenaxa — Strengths & Dosage Forms: Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
Dosage Forms & Available Strengths:
Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Reversibly binds lysine-binding sites on plasminogen and plasmin -> blocks plasmin from binding to fibrin -> stabilises preformed fibrin clots against fibrinolysis.

4. Therapeutic Indications & Evidence-Supported Uses

  • Heavy menstrual bleeding (menorrhagia)
  • postpartum haemorrhage (WOMAN trial protocol)
  • acute trauma haemorrhage (CRASH-2/3 protocol within 3 hours)
  • surgical/dental bleeding
  • hereditary angioedema
  • melasma (low-dose off-label)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Menorrhagia: 1 g (two 500 mg tablets) PO TDS-QDS for up to 4 days during menses (max 4 g/day). Trauma / Postpartum Haemorrhage: 1 g IV slowly over 10 min within 3 hours of onset, followed if needed by 1 g IV over 8 hours. • Paediatric: Major Bleeding / Trauma: 15-20 mg/kg (max 1 g) slow IV over 10 min.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
Elimination & Renal Adjustment:
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.
Hepatic Impairment Considerations:
Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Active thromboembolic disease (DVT, PE, cerebral thrombosis); subarachnoid haemorrhage; macroscopic haematuria from upper urinary tract (causes ureteric clot colic and obstruction); history of convulsions; NEVER administer intrathecally/epidurally. • Precautions: CATASTROPHIC LOOK-ALIKE AMPULE HAZARD: Tranexamic acid ampoules closely resemble Bupivacaine heavy spinal anaesthesia ampoules—accidental intrathecal injection causes refractory status epilepticus, ventricular arrhythmias, and >50% mortality! Store Tranexamic acid ampoules AWAY from spinal anaesthetic drugs.

Key Clinical Precautions: Renal: Excreted >95% unchanged in urine. Serum Creatinine 1.4-2.8 mg/dL: 10 mg/kg IV BD (or 50% oral dose); SCr 2.8-5.7 mg/dL: 10 mg/kg IV OD; SCr >5.7 mg/dL: 10 mg/kg IV q48h. • Hepatic: No dose adjustment required in hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, vomiting, diarrhoea, dizziness.
  • Venous or arterial thrombosis, retinal artery/vein occlusion, colour vision disturbance, convulsions (high IV doses in renal failure).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Combined oral contraceptives / Prothrombin complex concentrates / Factor IX -> increased thrombotic risk; Fibrinolytics (Alteplase, Streptokinase) -> mutual antagonism

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: For heavy periods, start tablets only after menstrual bleeding begins (for 3-5 days per cycle); stop immediately and seek medical care if leg swelling, chest pain, or visual changes occur.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 250 mg, 500 mg, 650 mg SR; Injection: 500 mg/5 mL (100 mg/mL ampoule).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.13] (p. 161)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.